(MGNX) MacroGenics - Ratings and Ratios
Bispecific Antibodies, Antibody-Drug Conjugates, T-Cell Engagers, B7-H3 Target
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 86.0% |
| Value at Risk 5%th | 122% |
| Relative Tail Risk | -13.50% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.37 |
| Alpha | -75.01 |
| CAGR/Max DD | -0.31 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.401 |
| Beta | 1.692 |
| Beta Downside | 0.935 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.06% |
| Mean DD | 56.52% |
| Median DD | 80.04% |
Description: MGNX MacroGenics November 17, 2025
MacroGenics, Inc. (NASDAQ: MGNX) is a clinical-stage biopharma focused on antibody-based cancer therapeutics in the United States, operating from Rockville, Maryland since its 2000 incorporation.
The pipeline centers on lorigerlimab, a bispecific DART that simultaneously blocks PD-1 and CTLA-4; it is currently in a Phase 2 trial for metastatic castration-resistant prostate cancer (mCRPC) and has shown a disease-control rate above 70% in early-stage data (assumption based on company press releases). Additional candidates include MGC026 (B7-H3-targeted ADC with a novel TOP1i payload), MGC028 (ADAM9-targeted ADC), and MGC030 (preclinical ADC), plus next-generation T-cell engagers.
MacroGenics maintains strategic collaborations with TerSera Therapeutics, Incyte, and Gilead, which provide non-dilutive funding and co-development expertise. As of the latest 10-Q (Q2 2024), the company reported cash and equivalents of roughly $150 million, giving it an estimated 12-month runway at current burn rates-a key liquidity metric for assessing near-term execution risk.
Sector-level drivers include a projected CAGR of ~12% for the global checkpoint-inhibitor market through 2030 and a historically high biotech financing environment, with U.S. venture capital allocations to oncology remaining above $10 billion annually. These macro trends support the commercial upside potential of lorigerlimab if Phase 2 endpoints are met.
If you’re looking to deepen your quantitative analysis of MGNX’s valuation assumptions, a quick dive into ValueRay’s model can surface the sensitivity of the stock to key inputs like trial success probabilities and cash-runway extensions.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-75.9m TTM) > 0 and > 6% of Revenue (6% = 7.56m TTM) |
| FCFTA -0.61 (>2.0%) and ΔFCFTA -37.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 148.9% (prev 115.3%; Δ 33.65pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.60 (>3.0%) and CFO -162.5m <= Net Income -75.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (63.3m) change vs 12m ago 0.66% (target <= -2.0% for YES) |
| Gross Margin 73.67% (prev 32.88%; Δ 40.80pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 47.08% (prev 53.43%; Δ -6.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -16.58 (EBITDA TTM -63.1m / Interest Expense TTM 4.26m) >= 6 (WARN >= 3) |
Altman Z'' -18.38
| (A) 0.69 = (Total Current Assets 232.1m - Total Current Liabilities 44.5m) / Total Assets 270.8m |
| (B) -4.54 = Retained Earnings (Balance) -1.23b / Total Assets 270.8m |
| warn (B) unusual magnitude: -4.54 — check mapping/units |
| (C) -0.26 = EBIT TTM -70.6m / Avg Total Assets 267.6m |
| (D) -6.03 = Book Value of Equity -1.23b / Total Liabilities 203.8m |
| Total Rating: -18.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 37.81
| 1. Piotroski 1.0pt |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.55 |
| 5. Debt/Ebitda 0.68 |
| 6. ROIC - WACC (= -102.9)% |
| 7. RoE -98.30% |
| 8. Rev. Trend 12.97% |
| 9. EPS Trend 26.76% |
What is the price of MGNX shares?
Over the past week, the price has changed by +12.42%, over one month by +36.09%, over three months by +5.23% and over the past year by -46.92%.
Is MGNX a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MGNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.4 | 87.8% |
| Analysts Target Price | 3.4 | 87.8% |
| ValueRay Target Price | 1.3 | -29.3% |
MGNX Fundamental Data Overview January 04, 2026
P/S = 0.798
P/B = 1.5201
P/EG = 0.01
Beta = 1.519
Revenue TTM = 126.0m USD
EBIT TTM = -70.6m USD
EBITDA TTM = -63.1m USD
Long Term Debt = 37.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.14m USD (from shortTermDebt, last quarter)
Debt = 37.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -43.1m USD (from netDebt column, last quarter)
Enterprise Value = -7.54m USD (101.8m + Debt 37.0m - CCE 146.4m)
Interest Coverage Ratio = -16.58 (Ebit TTM -70.6m / Interest Expense TTM 4.26m)
FCF Yield = 2185 % (FCF TTM -164.8m / Enterprise Value -7.54m)
FCF Margin = -130.8% (FCF TTM -164.8m / Revenue TTM 126.0m)
Net Margin = -60.23% (Net Income TTM -75.9m / Revenue TTM 126.0m)
Gross Margin = 73.67% ((Revenue TTM 126.0m - Cost of Revenue TTM 33.2m) / Revenue TTM)
Gross Margin QoQ = 81.63% (prev 59.96%)
Tobins Q-Ratio = -0.03 (set to none) (Enterprise Value -7.54m / Total Assets 270.8m)
Interest Expense / Debt = 9.03% (Interest Expense 3.34m / Debt 37.0m)
Taxrate = 0.0% (0.0 / 16.8m)
NOPAT = -70.6m (EBIT -70.6m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 5.22 (Total Current Assets 232.1m / Total Current Liabilities 44.5m)
Debt / Equity = 0.55 (Debt 37.0m / totalStockholderEquity, last quarter 67.0m)
Debt / EBITDA = 0.68 (negative EBITDA) (Net Debt -43.1m / EBITDA -63.1m)
Debt / FCF = 0.26 (negative FCF - burning cash) (Net Debt -43.1m / FCF TTM -164.8m)
Total Stockholder Equity = 77.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.03% (Net Income -75.9m / Total Assets 270.8m)
RoE = -98.30% (Net Income TTM -75.9m / Total Stockholder Equity 77.2m)
RoCE = -61.84% (EBIT -70.6m / Capital Employed (Equity 77.2m + L.T.Debt 37.0m))
RoIC = -91.49% (negative operating profit) (NOPAT -70.6m / Invested Capital 77.2m)
WACC = 11.39% (E(101.8m)/V(138.9m) * Re(12.25%) + D(37.0m)/V(138.9m) * Rd(9.03%) * (1-Tc(0.0)))
Discount Rate = 12.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.09%
Fair Price DCF = unknown (Cash Flow -164.8m)
EPS Correlation: 26.76 | EPS CAGR: 114.1% | SUE: 0.58 | # QB: 0
Revenue Correlation: 12.97 | Revenue CAGR: 54.81% | SUE: 2.07 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.66 | Chg30d=+0.025 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.72 | Chg30d=+1.063 | Revisions Net=+0 | Growth EPS=-94.0% | Growth Revenue=-35.2%
Additional Sources for MGNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle